X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs FRESENIUS KABI ONCO. - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES FRESENIUS KABI ONCO. DIVIS LABORATORIES/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 31.9 22.1 144.1% View Chart
P/BV x 5.2 3.1 166.2% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 DIVIS LABORATORIES   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
FRESENIUS KABI ONCO.
Mar-13
DIVIS LABORATORIES/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,222176 694.3%   
Low Rs78479 998.7%   
Sales per share (Unadj.) Rs153.137.7 406.3%  
Earnings per share (Unadj.) Rs39.95.1 784.3%  
Cash flow per share (Unadj.) Rs44.66.7 663.2%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.842.5 474.3%  
Shares outstanding (eoy) m265.47158.23 167.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.63.4 194.0%   
Avg P/E ratio x25.125.0 100.5%  
P/CF ratio (eoy) x22.518.9 118.8%  
Price / Book Value ratio x5.03.0 166.2%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,26620,135 1,322.4%   
No. of employees `0009.71.2 845.1%   
Total wages/salary Rs m4,687703 666.6%   
Avg. sales/employee Rs Th4,175.05,176.2 80.7%   
Avg. wages/employee Rs Th481.5610.4 78.9%   
Avg. net profit/employee Rs Th1,089.3699.6 155.7%   
INCOME DATA
Net Sales Rs m40,6435,963 681.6%  
Other income Rs m74918 4,160.6%   
Total revenues Rs m41,3925,981 692.1%   
Gross profit Rs m14,4601,430 1,011.1%  
Depreciation Rs m1,233258 478.2%   
Interest Rs m23-26 -86.9%   
Profit before tax Rs m13,9531,216 1,147.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m3,349342 978.7%   
Profit after tax Rs m10,604806 1,315.8%  
Gross profit margin %35.624.0 148.4%  
Effective tax rate %24.028.1 85.3%   
Net profit margin %26.113.5 193.1%  
BALANCE SHEET DATA
Current assets Rs m40,1055,102 786.1%   
Current liabilities Rs m6,5952,385 276.5%   
Net working cap to sales %82.545.6 181.0%  
Current ratio x6.12.1 284.4%  
Inventory Days Days119150 79.0%  
Debtors Days Days81113 71.2%  
Net fixed assets Rs m19,9955,148 388.4%   
Share capital Rs m531158 335.6%   
"Free" reserves Rs m53,0436,556 809.1%   
Net worth Rs m53,5746,732 795.8%   
Long term debt Rs m0952 0.0%   
Total assets Rs m61,58510,388 592.9%  
Interest coverage x618.4-45.8 -1,350.9%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.70.6 115.0%   
Return on assets %17.37.5 229.8%  
Return on equity %19.812.0 165.3%  
Return on capital %26.114.6 178.6%  
Exports to sales %074.5 0.0%   
Imports to sales %25.224.8 101.9%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs m10,2591,477 694.4%   
Fx inflow Rs m35,3845,298 667.9%   
Fx outflow Rs m10,3991,772 586.8%   
Net fx Rs m24,9853,525 708.7%   
CASH FLOW
From Operations Rs m11,4931,274 902.1%  
From Investments Rs m-11,372-1,204 944.3%  
From Financial Activity Rs m-93-196 47.5%  
Net Cashflow Rs m28-126 -22.5%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 11.8 0.3 3,933.3%  
FIIs % 19.0 9.6 197.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 9.1 189.0%  
Shareholders   31,796 42,599 74.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ALEMBIC PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  ASTRAZENECA PHARMA  BIOCON LTD  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 22, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - WOCKHARDT LTD. COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS